Many stocks, including several of the renowned Magnificent Seven, are still heavily impacted by the excitement surrounding the potential of artificial intelligence (AI). Investors who have been cautious about identifying trends early or those who may have arrived at the party prematurely might be contemplating whether now is the right time to join the frenzy. Have all the potential earnings from AI companies already materialized?
There could still be opportunities waiting to be uncovered. Spectral AI Inc., a medical diagnostics company based in Dallas and listed on NASDAQ under the symbol MDAI, serves as a prime example. While its stock price experienced a decline last year, it is now forecasted to more than double in the upcoming period. What factors are at play here? Let’s delve deeper.
A Promising Recovery for Spectral AI
| One-Year Price Change | Price as of the Last Update | Estimated Gain of 1% over the Previous Year |
|---|---|---|
| -83.0% | $4.00 | 132.6% |
The company’s objective is to provide medical tests that aid in making quicker and more precise decisions regarding wound care for individuals with burns and diabetic foot ulcers. Among Ethereal AI’s offerings is DeepView, a predictive medical tool that offers clinicians an objective and immediate assessment of a wound’s treatability before any medical intervention.
With a market capitalization of approximately $32 million, Spectral AI lags behind competitors like Medtronic PLC and Butterfly Network Inc. (NYSE: BFLY).
Spectral AI recently announced the establishment of a wholly-owned subsidiary dedicated to advancing intellectual property (IP) relevant to the broader AI landscape, particularly in healthcare.
In a recent board decision, Wensheng Fan, the company’s Chief Strategy Officer and Senior Advisor, was replaced by Peter Carlson, the Chief Financial Officer. Furthermore, the company reaffirmed its projected profit growth for 2024.
The stock saw a surge in October following the approval of the DeepView wound imaging system by U.K. regulators. Despite this, the stock remained below the post-IPO peak of nearly \(19 observed in early September. Subsequently, the stock dipped to around \)4 per share, potentially due to profit-taking activities and concerns among analysts and investors regarding a possible AI bubble formation.
Since its initial public offering, the shares have plummeted by over 82% and approximately 30% year-over-year. What lies ahead for them?
Who Is Backing This AI Stock?
An analyst initiated coverage of the stock in January with a Buy rating. According to BTIG analyst Ryan Zimmerman, the stock is expected to more than double in the next 12 months, citing the vast and underexplored market for advanced wound care. Additionally, the analyst foresees that Spectral AI’s subscription model will yield recurring revenue with substantial profit margins, potentially paving the way for a robust business.
Is this investment poised for growth and success this time around? At least one analyst believes it’s on the right track.
No Minimums, No Limits, No Velvet Ropes. (Sponsored)
Robinhood revolutionized commission-free trading and continues to do so today. With Robinhood Financial, you can trade options, leading mutual funds, and stocks such as Nvidia and Amazon seamlessly. Enjoy the added benefit of FDIC insurance.
Moreover, Robinhood Crypto enables you to buy and sell cryptocurrencies like Bitcoin (BTC), Ethereum (ETH), and Dogecoin (DOGE) effortlessly.
